Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy

Ivan J Suñer, Marc C Peden Retina Associates of Florida, Tampa, FL, USACorrespondence: Ivan J SuñerRetina Associates of Florida, 602 South MacDill Avenue, Tampa, FL, 33609, USAEmail ivansuner@gmail.comPurpose: To evaluate the safety and efficacy of a dexamethasone sustained-release intracanalicular...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Suñer IJ, Peden MC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	dexamethasone intracanalicular insert sustained-release drug delivery pars plana vitrectomy postoperative inflammation Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f45458c169ba471e830e4366bf28bb83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f45458c169ba471e830e4366bf28bb83
record_format	dspace
spelling	oai:doaj.org-article:f45458c169ba471e830e4366bf28bb832021-12-02T18:49:48ZDexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy1177-5483https://doaj.org/article/f45458c169ba471e830e4366bf28bb832021-09-01T00:00:00Zhttps://www.dovepress.com/dexamethasone-sustained-release-intracanalicular-insert-for-control-of-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Ivan J Suñer, Marc C Peden Retina Associates of Florida, Tampa, FL, USACorrespondence: Ivan J SuñerRetina Associates of Florida, 602 South MacDill Avenue, Tampa, FL, 33609, USAEmail ivansuner@gmail.comPurpose: To evaluate the safety and efficacy of a dexamethasone sustained-release intracanalicular insert (DII) (Dextenza® Ocular Therapeutix, Inc., Bedford, MA) for control of inflammation and pain after pars plana vitrectomy (PPV) compared to standard topical steroid therapy.Methods: Retrospective, case-matched comparison of consecutive patients undergoing PPV. Control patients were matched by diagnosis and procedure performed. The primary outcome was the proportion of patients with complete anterior chamber cell clearance (ACCC) at postoperative day 7. Secondary outcomes included proportion developing intraocular pressure (IOP) > 25 mmHg, change in mean optical coherence tomography central foveal thickness (OCT CFT), and proportion developing cystoid macular edema (CME) on qualitative analysis of OCT.Results: The DII group had a statistically significant higher rate of complete ACCC compared to the topical steroid group (65% versus 35%, respectively, with p=0.01). No eyes had IOP > 25 mmHg in the DII, compared to 2 eyes in the topical steroid group (not statistically significant). Overall, mean OCT CFT decreased in both groups; one patient had CME in the DII group, as compared to three in the topical steroid group (not statistically significant).Conclusion: The dexamethasone intracanalicular insert provided excellent safety and efficacy in control of postoperative inflammation following PPV in this retrospective case-matched study.Keywords: dexamethasone intracanalicular insert, sustained-release drug delivery, pars plana vitrectomy, postoperative inflammation, PPVSuñer IJPeden MCDove Medical Pressarticledexamethasone intracanalicular insertsustained-release drug deliverypars plana vitrectomypostoperative inflammationOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 3859-3864 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	dexamethasone intracanalicular insert sustained-release drug delivery pars plana vitrectomy postoperative inflammation Ophthalmology RE1-994
spellingShingle	dexamethasone intracanalicular insert sustained-release drug delivery pars plana vitrectomy postoperative inflammation Ophthalmology RE1-994 Suñer IJ Peden MC Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy
description	Ivan J Suñer, Marc C Peden Retina Associates of Florida, Tampa, FL, USACorrespondence: Ivan J SuñerRetina Associates of Florida, 602 South MacDill Avenue, Tampa, FL, 33609, USAEmail ivansuner@gmail.comPurpose: To evaluate the safety and efficacy of a dexamethasone sustained-release intracanalicular insert (DII) (Dextenza® Ocular Therapeutix, Inc., Bedford, MA) for control of inflammation and pain after pars plana vitrectomy (PPV) compared to standard topical steroid therapy.Methods: Retrospective, case-matched comparison of consecutive patients undergoing PPV. Control patients were matched by diagnosis and procedure performed. The primary outcome was the proportion of patients with complete anterior chamber cell clearance (ACCC) at postoperative day 7. Secondary outcomes included proportion developing intraocular pressure (IOP) > 25 mmHg, change in mean optical coherence tomography central foveal thickness (OCT CFT), and proportion developing cystoid macular edema (CME) on qualitative analysis of OCT.Results: The DII group had a statistically significant higher rate of complete ACCC compared to the topical steroid group (65% versus 35%, respectively, with p=0.01). No eyes had IOP > 25 mmHg in the DII, compared to 2 eyes in the topical steroid group (not statistically significant). Overall, mean OCT CFT decreased in both groups; one patient had CME in the DII group, as compared to three in the topical steroid group (not statistically significant).Conclusion: The dexamethasone intracanalicular insert provided excellent safety and efficacy in control of postoperative inflammation following PPV in this retrospective case-matched study.Keywords: dexamethasone intracanalicular insert, sustained-release drug delivery, pars plana vitrectomy, postoperative inflammation, PPV
format	article
author	Suñer IJ Peden MC
author_facet	Suñer IJ Peden MC
author_sort	Suñer IJ
title	Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy
title_short	Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy
title_full	Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy
title_fullStr	Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy
title_full_unstemmed	Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy
title_sort	dexamethasone sustained-release intracanalicular insert for control of postoperative inflammation after pars plana vitrectomy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/f45458c169ba471e830e4366bf28bb83
work_keys_str_mv	AT sunerij dexamethasonesustainedreleaseintracanalicularinsertforcontrolofpostoperativeinflammationafterparsplanavitrectomy AT pedenmc dexamethasonesustainedreleaseintracanalicularinsertforcontrolofpostoperativeinflammationafterparsplanavitrectomy
_version_	1718377599570280448

Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy

Ejemplares similares